ライフサイエンスコーパス: positive airway pressure

1 pressure control system (5 cm H2O continuous positive airway pressure).

2 he first line of therapy is nasal continuous positive airway pressure.

3 t were superimposed on a baseline continuous positive airway pressure.

4 usion of lungs held motionless by continuous positive airway pressure.

5 assisted spontaneous breathing, and biphasic positive airway pressure.

6 increase in the duration of nasal continuous positive airway pressure.

7 to 0.40 and received 5 cm H2O of continuous positive airway pressure.

8 ith supplemental oxygen and nasal continuous positive airway pressure.

9 -by methods in patients receiving continuous positive airway pressure.

10 ) during spontaneous breathing or continuous positive airway pressure.

11 ith a GA less than 34 weeks under continuous positive airway pressure.

12 ratory pressure support on top of expiratory positive airway pressure.

13 in the first hours of life under continuous positive airway pressure.

14 or patients who are intolerant to continuous positive airway pressure.

15 early introduction of less invasive forms of positive airway pressure.

16 pressure support ventilation and continuous positive airway pressure (0.46+/-0.11 L and 0.44+/-0.11

17 ect of increased airway pressure (continuous positive airway pressure, 20 cm H2O; n = 12) and simulat

18 nimals underwent lung recruitment continuous positive airway pressure 40 cm H2O for 40 secs to normal

19 preextubation trial (FIO2 = 0.21, continuous positive airway pressure = 5 cm H2O [0.5 kPa]).

20 dolescents, a group that has poor continuous positive airway pressure adherence and difficulty in ach

21 Compared with biphasic positive airway pressure/airway pressure release ventila

22 pressure release ventilation of 0%, biphasic positive airway pressure/airway pressure release ventila

23 Biphasic positive airway pressure/airway pressure release ventila

24 lammation, and damage compared with biphasic positive airway pressure/airway pressure release ventila

25 piratory distress syndrome in pigs, biphasic positive airway pressure/airway pressure release ventila

26 Biphasic positive airway pressure/airway pressure release ventila

27 on (n = 9 per group, 6 hr each): 1) biphasic positive airway pressure/airway pressure release ventila

28 ressure release ventilation, 0%; 2) biphasic positive airway pressure/airway pressure release ventila

29 re release ventilation, > 0-30%; 3) biphasic positive airway pressure/airway pressure release ventila

30 lease ventilation, > 30-60%, and 4) biphasic positive airway pressure/airway pressure release ventila

31 The old modes of continuous positive airway pressure and bilevel positive airway pre

32 Studies show that continuous positive airway pressure and non-invasive positive press

33 mmarize the current management of continuous positive airway pressure and noninvasive positive pressu

34 to surgical treatment, the use of continuous positive airway pressure and noninvasive positive pressu

35 use of NRS including preinduction continuous positive airway pressure and postextubation NRS for high

36 pulmonary artery pressure in both continuous positive airway pressure and pressure control groups imm

37 L, Total Face) were tested during continuous positive airway pressure and pressure support ventilatio

38 itive pressure ventilation (i.e., continuous positive airway pressure and/or intubation).

39 ntained at a therapeutic level of continuous positive airway pressure, and nasal pressure was acutely

40 on for ventilation treatment with continuous positive airway pressure, and other potential ocular and

41 al lung aeration within 48 hrs of continuous positive airway pressure applied via the endobronchial b

42 Subjects were ventilated with continuous positive airway pressure at 5 cm H2O, spontaneous ventil

43 re techniques such as continuous and bilevel positive airway pressure avoid intubation and its attend

44 Noninvasive ventilation delivered as bilevel positive airway pressure (BiPAP) is often used to avoid

45 n: (1) patients with OSAS without continuous positive airway pressure (CPAP) (n = 13); (2) patients w

46 +/- 0.3 cmH(2)O l(-1) s; optimal continuous positive airway pressure (CPAP) = 11.3 +/- 0.7 cmH(2)O)

47 mine how long-term treatment with continuous positive airway pressure (CPAP) affects cardiac autonomi

48 Continuous positive airway pressure (CPAP) and mandibular advanceme

49 dence for and the clinical use of continuous positive airway pressure (CPAP) and positive end-expirat

50 Data regarding the use of continuous positive airway pressure (CPAP) and recurrence of AF wer

51 repositioning splints (MRSs) and continuous positive airway pressure (CPAP) are used to treat the sl

52 Although continuous positive airway pressure (CPAP) can mitigate these risks

53 Meta-analysis found that continuous positive airway pressure (CPAP) compared with sham was s

54 ea Symptoms Questionnaire (SASQ), continuous positive airway pressure (CPAP) compliance, and physicia

55 rapeutic and economic benefits of continuous positive airway pressure (CPAP) for moderate to severe o

56 ngly popular alternative to nasal continuous positive airway pressure (CPAP) for noninvasive respirat

57 nclear whether OSA treatment with continuous positive airway pressure (CPAP) has metabolic benefits.

58 xygen therapy delivered by bubble continuous positive airway pressure (CPAP) improved outcomes compar

59 Continuous positive airway pressure (CPAP) in asthma patients with

60 Continuous positive airway pressure (CPAP) is considered the treatm

61 ulmonary resuscitation (CPR), but continuous positive airway pressure (CPAP) is increasingly discusse

62 Continuous positive airway pressure (CPAP) is the first-line treatm

63 Nasal continuous positive airway pressure (CPAP) is the treatment of choi

64 Continuous positive airway pressure (CPAP) is the treatment of choi

65 Although continuous positive airway pressure (CPAP) is used frequently for p

66 Continuous positive airway pressure (CPAP) is used to minimize airw

67 le 3-min 'drops' from therapeutic continuous positive airway pressure (CPAP) levels.

68 py in patients who cannot tolerate continous positive airway pressure (CPAP) machines or intraoral de

69 Adherence to short-term continuous positive airway pressure (CPAP) may predict long-term us

70 sought to determine the effect of continuous positive airway pressure (CPAP) of patients with OSA on

71 ttle evidence about the effect of continuous positive airway pressure (CPAP) on glycemic control in p

72 termine the short-term effects of continuous positive airway pressure (CPAP) on sleep-disordered brea

73 r study of the effects of 4 wk of continuous positive airway pressure (CPAP) or oral placebo on 24-h

74 yndrome in premature infants with continuous positive airway pressure (CPAP) preserves surfactant and

75 Continuous positive airway pressure (CPAP) reduces blood pressure,

76 ce of lung volume on the level of continuous positive airway pressure (CPAP) required to prevent flow

77 Continuous positive airway pressure (CPAP) therapy is the most comm

78 tudy was to examine the effect of continuous positive airway pressure (CPAP) therapy on atrial fibril

79 The effects of continuous positive airway pressure (CPAP) therapy on endothelial f

80 nce of spontaneous breathing with continuous positive airway pressure (CPAP) therapy on the relative

81 Short-term studies indicate that continuous positive airway pressure (CPAP) therapy reduces blood pr

82 hese patients had been prescribed continuous positive airway pressure (CPAP) therapy to manage OSA an

83 Prolonged continuous positive airway pressure (CPAP) therapy with supplementa

84 ested after at least two weeks of continuous positive airway pressure (CPAP) therapy.

85 after compliance-monitored nasal continuous positive airway pressure (CPAP) therapy.

86 e inspiratory flow contour during continuous positive airway pressure (CPAP) titration in obstructive

87 ce (V D) and can be combined with continuous positive airway pressure (CPAP) to decrease minute volum

88 y, endothelium, inflammation, and continuous positive airway pressure (CPAP) to identify peer-reviewe

89 kefulness with the application of continuous positive airway pressure (CPAP) to the upper airway.

90 ), the blood pressure response to continuous positive airway pressure (CPAP) treatment is highly vari

91 ttle evidence about the effect of continuous positive airway pressure (CPAP) treatment on blood press

92 btherapeutic (0-1 cm H(2)O) nasal continuous positive airway pressure (CPAP) treatment on polysomnogr

93 e (CHD) in women, and the role of continuous positive airway pressure (CPAP) treatment on this associ

94 ized therapeutic decision-making, continuous positive airway pressure (CPAP) treatment or a healthy h

95 ted the hypothesis that long-term continuous positive airway pressure (CPAP) treatment will decrease

96 sensory evaluation in response to continuous positive airway pressure (CPAP) treatment.

97 We tested the hypothesis that continuous positive airway pressure (CPAP) use and outcomes can be

98 noninvasive ventilation (NIV) and continuous positive airway pressure (CPAP) use in patients with OHS

99 in blood pressure associated with continuous positive airway pressure (CPAP) use, with smaller or unc

100 our trial of early treatment with continuous positive airway pressure (CPAP) versus early surfactant

101 ng basal breathing (BB) and nasal continuous positive airway pressure (CPAP) was applied to reduce ne

102 ecrement in muscle activity nasal continuous positive airway pressure (CPAP) was applied to reduce ne

103 efficacy similar to that of nasal continuous positive airway pressure (CPAP) when used as postextubat

104 We delivered continuous positive airway pressure (CPAP) with the helmet under a

105 We aimed to determine if continuous positive airway pressure (CPAP), a form of non-invasive

106 r liter to receive treatment with continuous positive airway pressure (CPAP), a weight-loss intervent

107 treatment for symptomatic OSA is continuous positive airway pressure (CPAP), but its value in patien

108 fter 60 d of treatment with nasal continuous positive airway pressure (CPAP), E(max) to bradykinin ro

109 (AC), pressure support (PS), and continuous positive airway pressure (CPAP), separately with a dry a

110 liminated by application of nasal continuous positive airway pressure (CPAP), SPC-muscle activity was

111 in SNA through the application of continuous positive airway pressure (CPAP), which remains a primary

112 ssure ventilation (IPPV) or nasal continuous positive airway pressure (CPAP)--at the time of the firs

113 d only for their SDB, using nasal continuous positive airway pressure (CPAP).

114 p and during application of nasal continuous positive airway pressure (CPAP).

115 arison to the standard therapy of continuous positive airway pressure (CPAP).

116 re well treated and adherent with continuous positive airway pressure (CPAP).

117 Noninvasive ventilation (continuous positive airway pressure [CPAP] or noninvasive intermitt

118 fterward, patients were placed on continuous positive airway pressure for 1-2 mins to measure their s

119 t effective treatment of OSA with continuous positive airway pressure for 3 months significantly redu

120 airway pressure of 30 cm H2O: 1) continuous positive airway pressure for 30 seconds (CPAP-30); 2) st

121 recruitment maneuvers: 40 cm H2O continuous positive airway pressure for 60 secs and 40 cm H2O posit

122 ed as an alternative treatment to continuous positive airway pressure for patients with obstructive s

123 al infarction rate was higher in the bilevel positive airway pressure group (71%) compared with both

124 At 30 mins; the bilevel positive airway pressure group had greater reductions in

125 in diastolic blood pressure occurred in the positive airway pressure group than in the usual care gr

126 7 +/- 1.2 kPa]) were observed in the bilevel positive airway pressure group, as were significant impr

127 In both the control group and continuous positive airway pressure groups, Pao2 did not significan

128 ed in OSA patients who adhered to continuous positive airway pressure >/=4 hours daily.

129 gh-flow nasal cannula therapy and continuous positive airway pressure had similar efficacy (RR, 1.11;

130 ent to ventilation treatment with continuous positive airway pressure have an increased risk of secon

131 tinuous positive airway pressure and bilevel positive airway pressure have been actively introduced i

132 farctions associated with the use of bilevel positive airway pressure highlights the need for further

133 Nasal continuous positive airway pressure immediately normalized the brea

134 ns unclear whether treatment with continuous positive airway pressure improves daytime function in th

135 t of obstructive sleep apnea with continuous positive airway pressure improves not only patient-repor

136 Bilevel positive airway pressure improves ventilation and vital

137 t device, the main alternative to continuous positive airway pressure, improves endothelial function

138 function improved after starting continuous positive airway pressure in asthmatics with moderate to

139 nce to ventilation treatment with continuous positive airway pressure in patients with severe OSAS in

140 ssure ventilation was superior to continuous positive airway pressure in preventing extubation failur

141 Data as to the efficacy of continuous positive airway pressure in severe OSA have come from ra

142 nts were randomized to receive nasal bilevel positive airway pressure (inspiratory and expiratory pos

143 Continuous positive airway pressure is a useful second-line treatme

144 Continuous positive airway pressure is the treatment of choice, wit

145 sleep center; both plans included continuous positive airway pressure, mandibular advancement splints

146 OSA subjects were treated with continuous positive airway pressure (mean duration of 26 weeks), af

147 g the ventilator while set in the continuous positive airway pressure mode were administered in rando

148 piratory cycles with supporting a continuous positive airway pressure model.

149 mized to auto-titrating CPAP (n = 122) or no positive airway pressure (n = 122).

150 bstructive sleep apnea with nasal continuous positive airway pressure (nasal CPAP) will decrease auto

151 Nasal continuous positive airway pressure (NCPAP) is widely used as a tre

152 tory support noninferior to nasal continuous positive airway pressure (nCPAP) or bilevel nCPAP (BiPAP

153 m infants is optimal: noninvasive continuous positive airway pressure (NCPAP) or intubate-surfactant-

154 pressure can be reduced by nasal continuous positive airway pressure (nCPAP), such treatment could r

155 right (control) lung was kept on continuous positive airway pressure of 20 cm H2O, and CO2 was parti

156 home ventilator settings were an inspiratory positive airway pressure of 24 (IQR, 22-26) cm H2O, an e

157 ure of 24 (IQR, 22-26) cm H2O, an expiratory positive airway pressure of 4 (IQR, 4-5) cm H2O, and a b

158 on during airway occlusion and on continuous positive airway pressure of 5 and pressure support of 10

159 airway pressure (inspiratory and expiratory positive airway pressures of 15 and 5 cm H2O, respective

160 upported the beneficial effect of continuous positive airway pressure on quality of life, mood, and w

161 Bi-level positive airway pressure or adaptive servo-ventilation c

162 in the first 72 hours (the use of continuous positive airway pressure or high-flow nasal cannula for

163 the major obstacle to successful continuous positive airway pressure or noninvasive positive pressur

164 Tidal volume during continuous positive airway pressure or pressure support ventilation

165 that required a mask, continuous or bilevel positive airway pressure, or mechanical ventilation were

166 pnea symptoms, adherence to using continuous positive airway pressure, patient satisfaction, and heal

167 upport ventilation as a 35 cm H2O continuous positive airway pressure period lasting 3-4 seconds at d

168 t and underwent a 20-min room air-continuous positive airway pressure preextubation trial (FIO2 = 0.2

169 classes: spontaneous breathing or continuous positive airway pressure; pressure support ventilation 5

170 Although regulated continuous positive airway pressure, pulse oximeters, and blenders

171 iac output immediately after some continuous positive airway pressure recruitment maneuvers and a sig

172 ry, deep breathing exercises, and continuous positive airway pressure) reduce pulmonary risk.

173 Continuous positive airway pressure reduced extubation failure in c

174 In conclusion, NPPV with bilevel positive airway pressure reduces the rate of ETI in pati

175 ailure during a room air-5 cm H2O continuous positive airway pressure, spontaneous breathing, preextu

176 Bilevel positive airway pressure support ventilation failure was

177 The efficacy of bilevel positive airway pressure support ventilation in selected

178 Bilevel positive airway pressure support ventilation.

179 entilatory support were treated with bilevel positive airway pressure support ventilation.

180 ssure triggering of a demand-flow continuous positive airway pressure system creates an effect simila

181 er of ventilation measured during continuous positive airway pressure, T piece, or pressure support v

182 ward more aggressive use of nasal continuous positive airway pressure, the optimal timing of exogenou

183 Continuous positive airway pressure, the treatment of choice for ob

184 as significant in those who were adherent to positive airway pressure therapy (-4.4 mm Hg vs. -1.6 mm

185 a significant reduction in sleepiness in the positive airway pressure therapy group (P < 0.0001).

186 , and mental component summary scores in the positive airway pressure therapy group.

187 performed at baseline and after 3 months of positive airway pressure therapy in a heterogeneous grou

188 Positive airway pressure therapy is frequently used to t

189 This trial showed no effect of positive airway pressure therapy on glycemic control in

190 ation index of 15 or more events per hour to positive airway pressure therapy or to usual care.

191 In OSA patients, continuous positive airway pressure therapy resulted in reduction o

192 However, it is not known whether positive airway pressure therapy results in improvements

193 Positive airway pressure therapy was associated with sig

194 We hypothesized that positive airway pressure therapy would be associated wit

195 ioral function in children after 3 months of positive airway pressure therapy, even in developmentall

196 After 4 weeks of continuous positive airway pressure therapy, flow-mediated dilation

197 me who are regular users of nasal continuous positive airway pressure therapy.

198 ness despite regular use of nasal continuous positive airway pressure therapy.

199 nother patient required noninvasive biphasic positive airway pressure throughout his course.

200 r treatment of confirmed OSA with continuous positive airway pressure to reduce driving risk, rather

201 stimulant medications or empiric continuous positive airway pressure to reduce driving risk.

202 e measured by repeatedly lowering continuous positive airway pressure to subtherapeutic levels for 3

203 lung isolation and application of continuous positive airway pressure to the left lung for 48 hrs.

204 RECOMMENDATION 2: ACP recommends continuous positive airway pressure treatment as initial therapy fo

205 ices as an alternative therapy to continuous positive airway pressure treatment for patients diagnose

206 Continuous positive airway pressure treatment improves the function

207 Continuous positive airway pressure treatment was associated with r

208 Patients who received continuous positive airway pressure treatment were significantly le

209 -year incidences of both OSA (AHI of >/=5 or positive airway pressure treatment) and OSA concomitant

210 ized to 8 weeks of active or sham continuous positive airway pressure treatment.

211 am arm received 8 weeks of active continuous positive airway pressure treatment.

212 nd in the morning after effective continuous positive airway pressure treatment.

213 h adverse effects associated with continuous positive airway pressure treatment.

214 e for high-flow nasal cannula and continuous positive airway pressure use in a monitored setting to p

215 ess the effects of treatment with continuous positive airway pressure versus conservative therapy (CT

216 for randomized clinical trials of continuous positive airway pressure versus mechanical ventilation.

217 d for narcolepsy and hypersomnia; continuous positive airway pressure, weight loss, surgery, and oral

218 Nasal continuous positive airway pressure when OSAS was diagnosed.

219 e-pressure ventilation (NPPV), using bilevel positive airway pressure, with usual medical care (UMC)

220 ugh most infants were ventilated, continuous positive airway pressure without ventilation increased f